← back to search

Jing-Xia Guo

Xinjiang University · CN
Area of research
Epidemiology · Hepatology
Research interest
Research interests include Biology, Virology, Cell biology, GTPase, Guanine nucleotide exchange factor, and Viral replication.
h-index
citations
25
works
5
NIH funding
primary concept
email

Recent publications

Rho-GTPases subfamily: cellular defectors orchestrating viral infection
Cellular & Molecular Biology Letters 2025cited by 14position: middledoi
Complex Reassortment Dynamics of H9N2 Avian Influenza Viruses in Xinjiang, China: Implications for Zoonotic Spillover
Influenza and Other Respiratory Viruses 2025cited by 3position: middledoi
Rap1b: A cytoskeletal regulator Advantageous to viral infection
iScience 2024cited by 3position: middledoi
Response to HIV-1 gp160-carrying recombinant virus HSV-1 and HIV-1 VLP combined vaccine in BALB/c mice
Frontiers in Microbiology 2023cited by 2position: middledoi
Expression and immunogenicity of recombinant glycoprotein D of herpes simplex virus 1 in <i>Drosophila</i> S2 cells
Preparative Biochemistry & Biotechnology 2016cited by 3position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Zhenghai Ma · Xinjiang University5 papers (2016–2025)Beibei Zhang · Nanjing University of Chinese Medicine3 papers (2023–2025)Hongyan Mao · Xinjiang University2 papers (2016–2023)Shuli Li · Shandong Tumor Hospital2 papers (2024–2025)Juntao Ding · Xinjiang University2 papers (2024–2025)Hongjuan Zhu · Xinjiang University2 papers (2016–2023)Kamila Aisaiti · Xinjiang University1 papers (2025–2025)Yuhai Bi · Xinjiang Agricultural University1 papers (2025–2025)Tong Tong Wu · Tulane University1 papers (2025–2025)Nana Chang · Xinjiang University1 papers (2025–2025)Xiaofei Zhao · Shandong University1 papers (2016–2016)Fei Du · Fudan University1 papers (2025–2025)Hong Duan · Nanchang University1 papers (2025–2025)Cheng Zhang · The Ohio State University Wexner Medical Center1 papers (2025–2025)Han Du · University of Wollongong1 papers (2025–2025) · 1 papers (2023–2023)